Evidence map›Paper›PMID 31581492›Full record

ArticlePharmaceutics2019

Assessment of the Inter-Batch Variability of Microstructure Parameters in Topical Semisolids and Impact on the Demonstration of Equivalence.

Víctor Mangas-Sanjuán, María Pleguezuelos-Villa, Matilde Merino-Sanjuán, Mª Jesús Hernández, Amparo Nácher, Alfredo García-Arieta, Daniel Peris, Irene Hidalgo, Lluís Soler, Marta Sallan and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Víctor Mangas-SanjuánDepartamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Av. Vicente Andrés Estellés s/n, Burjassot, 46100 Valencia, Spain. victor.mangas@uv.e.
María Pleguezuelos-VillaDepartamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Av. Vicente Andrés Estellés s/n, Burjassot, 46100 Valencia, Spain. maplevi@alumni.uv.es.
Matilde Merino-SanjuánDepartamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Av. Vicente Andrés Estellés s/n, Burjassot, 46100 Valencia, Spain. matilde.merino@uv.es.
Mª Jesús HernándezDepartament de Fisica de la Terra i Termodinàmica, Universitat de València, Vicente Andrés Estelles s/n. Burjassot, 46100 Valencia, Spain. M.Jesus.Hernandez@uv.es.
Amparo NácherDepartamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Av. Vicente Andrés Estellés s/n, Burjassot, 46100 Valencia, Spain. amparo.nacher@uv.es.ORCID 0000-0002-1707-7966
Alfredo García-ArietaDivisión de Farmacología y Evaluación Clínica, Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, Calle Campezo 1, Ed 8, 28022 Madrid, Spain. agarciaarieta@gmail.com.ORCID 0000-0002-9702-6973
Daniel PerisPharmacokinetics and Clinical Affairs Department, Strategy and Development Area, Kern Pharma S.L., Calle Venus 72, Terrassa, 08228 Barcelona, Spain. danielperis@outlook.es.
Irene HidalgoPharmacokinetics and Clinical Affairs Department, Strategy and Development Area, Kern Pharma S.L., Calle Venus 72, Terrassa, 08228 Barcelona, Spain. ihidalgom@kernpharma.com.
Lluís SolerFormulation and Late Scale Development Department, Strategy and Development Area. Kern Pharma S.L., Calle Venus 72, Terrassa, 08228 Barcelona, Spain. lsoler@kernpharma.com.
Marta SallanFormulation and Late Scale Development Department, Strategy and Development Area. Kern Pharma S.L., Calle Venus 72, Terrassa, 08228 Barcelona, Spain. msallan@kernpharma.com.
Virginia MerinoDepartamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Av. Vicente Andrés Estellés s/n, Burjassot, 46100 Valencia, Spain. Virginia.Merino@uv.es.
Universitat de València · ESLight Prescriptions Innovators (Spain) · ESAgencia Española de Medicamentos y Productos Sanitarios · ES

Funding

Kern Pharma S.L. Not applicable
6 · The paper itself

Abstract

Demonstration of similar microstructure is essential for demonstrating the equivalence of generic topical products since the microstructure of semisolids may affect the drug release. The objective of this study was to compare the microstructure-defining physical parameters of different batches of a reference ointment containing calcipotriol and betamethasone (Daivobet 50 µg/0.5 mg/g) in order to define the acceptance range that allows concluding equivalence between these batches. Being batches of the same reference product, they are expected to be clinically equivalent and possess similar microstructure. The 90% confidence intervals for the test/reference ratio of these physical parameters were calculated with parametric and non-parametric approaches. Both methods conclude that equivalent microstructure between batches cannot be demonstrated with a reasonable sample size when the acceptance range was set at ±10%, since several physical parameters exhibit inter-batch variability >10%. An acceptance range of ±10% is therefore too strict to conclude equivalence in the microstructure of semisolid dosage forms, given the inter-batch variability observed between batches of the reference product. A wider fixed acceptance range or an acceptance range widened based on the inter-batch variability of the reference product would be advisable.

Indexed as

equivalencegeneric semisolid formulationinter-batch variabilitymicrostructurerheologytopical drug

Identifiers

PMID31581492
PMCPMC6835722
OpenAlexW2977756606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.